L
Lemonex
Biotech & Life Sciences · Seoul, South Korea · Founded 2013
Innovative drug delivery and screening technologies for gene therapy, cancer immunotherapy, and antiviral drugs MoreLess
Lemonex is a global biotherapeutics biotechnology company specializing in next-generation drug delivery and biosensor technologies. The company's core product, DegradaBALL, enables precise control over drug size, concentration, and stability, making it highly effective for gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. Lemonex also offers PANGO technology, a cutting-edge drug screening platform optimized for rapid identification of antiviral drugs from extensive drug candidate libraries.
Lemonex serves pharmaceutical companies and research institutions focused on developing advanced therapeutic agents. Operating in the biotherapeutics market, the company generates revenue through the commercialization of its proprietary technologies and collaborative partnerships.
Keywords: biotherapeutics, drug delivery, gene therapy, cancer immunotherapy, antibody therapy, synthetic drugs, biosensor technology, antiviral drugs, drug screening, biotechnology.
Company overview
Lemonex company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Seoul, South Korea
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 72.7
Valuation & funding
Lemonex funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Apr 2021 | $13M | $52M | SmileGate Investment · Metaine Best · Division Investment | ↗ |
| SERIES B✓Equity / VC | Dec 2018 | $9.6M | $39M | Daesung Private Equity Group · Shinhan Capital · IBK Capital · Union Investment Partners | ↗ |
| SERIES AEquity / VC | Mar 2018 | $2.9M | $12M | Daekyo Investment · L&S Venture Capital | ↗ |
| SPINOUT✓Other financing | Jan 2013 | $0 | — | Seoul National University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 6 |
| 2025 | 7 |
| 2024 | 8 |
| 2023 | 7 |
| 2022 | 9 |
| 2021 | 7 |
Growth signals
Lemonex website traffic
Latest recorded traffic for Lemonex is 2.8K monthly website visits, up 55.6% over the last three months. Lemonex's team declined 14.3% over the past year.
Comparisons
Lemonex compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Lemonex's talent
Source: Dealroom Talent Intelligence.
Investors
15 investors on Lemonex's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Lemonex has talent and traffic
team presence
In the news
Latest news about Lemonex
Recent press, funding announcements, and product moves mentioning Lemonex — open to read from the original sources.
Market sentiment
What the market is saying about Lemonex
An AI-synthesized read of the highest-engagement posts about Lemonex on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lemonex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.